(211 days)
Not Found
No.
The document describes a heat therapy system for dry eye disease. It focuses on controlled temperature delivery and mentions no components or functionalities that suggest the presence of an AI model, such as machine learning for diagnostics, treatment planning, or adaptive control beyond set temperature ranges.
Yes
The device is intended for the application of localized heat therapy to treat evaporative dry eye disease due to meibomian gland dysfunction, which clearly indicates a therapeutic purpose.
No
The device is described as providing localized heat therapy and is used to treat dry eye disease. It does not mention any function for diagnosing conditions or diseases.
No
The device description clearly outlines hardware components such as a reusable SmartHub, SmartCable, Charging Nest, charging adapter, and single-use SmartLids. The system delivers controlled heat and is operated by physically connecting these components, indicating it is not a software-only medical device.
No.
The device is intended for the application of localized heat therapy for dry eye disease due to meibomian gland dysfunction, which is a therapeutic rather than a diagnostic purpose. It does not analyze human specimens.
N/A
Intended Use / Indications for Use
The TearCare MGX System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.
Product codes
ORZ
Device Description
The TearCare MGX System is designed to deliver controlled, precise heat to the tarsal plates and underlying meibomian glands of the eyelids for 15 minutes, followed by an optional warming hold time of up to 10 minutes to allow for manual expression. The TearCare MGX System is comprised of a reusable SmartHub, SmartCable, Charging Nest and charging adapter, and single use SmartLids.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Eyelids, tarsal plates, meibomian glands
Indicated Patient Age Range
Adult patients
Intended User / Care Setting
Eye care practitioner / In-Office
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Clinical Validation Study:
- study type: Clinical validation study to validate the fit and retention of the TearCare MGX System earloop using modified Instructions for Use.
- sample size: 21 subjects
- AUC: Not Found
- MRMC: Not Found
- standalone performance: Not Found
- key results: The TearCare MGX System was applied to 21 subjects. The study evaluated updated instructions for use regarding additional steps to "check for earpiece fitment," in order to assess whether the ear loops are properly installed and ensure that they can remain stable without the need for additional support. If a patient is identified through the earpiece fitment check to have "loose" fitment, then the eye care practitioner may proceed to use surgical tape to secure the earpiece. All earloop components remained affixed to the ears in all subjects for the duration of the 25 minute simulated treatment. The results of this clinical validation study demonstrate that the TearCare MGX device components remain securely affixed to the eyelid and head throughout a simulated 25 minute treatment when the SmartLids are applied according to updated instructions for use.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.5200 Eyelid thermal pulsation system.
(a)
Identification. An eyelid thermal pulsation system is an electrically-powered device intended for use in the application of localized heat and pressure therapy to the eyelids. The device is used in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye. The system consists of a component that is inserted around the eyelids and a component to control the application of heat and pressure to the eyelids.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Appropriate analysis/testing should validate electromagnetic compatibility (EMC) and safety of exposure to non-ionizing radiation;
(2) Design, description, and performance data should validate safeguards related to the temperature and pressure aspects of the device, including during fault conditions;
(3) Performance data should demonstrate the sterility of patient-contacting components and the shelf-life of these components;
(4) The device should be demonstrated to be biocompatible; and
(5) Performance data should demonstrate that any technological changes do not adversely effect safety and effectiveness.
FDA 510(k) Clearance Letter - TearCare MGX System
Page 1
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
Doc ID # 04017.07.05
Sight Sciences, Inc.
Rachel Franco
Principal Regulatory Affairs Specialist
4040 Campbell Avenue
Suite 100
Menlo Park, CA 94025
Re: K242786
Trade/Device Name: TearCare MGX System
Regulation Number: 21 CFR 886.5200
Regulation Name: Eyelid Thermal Pulsation System
Regulatory Class: Class II
Product Code: ORZ
Dated: March 14, 2025
Received: March 17, 2025
Dear Rachel Franco:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
April 15, 2025
Page 2
K242786 - Rachel Franco Page 2
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic.
Page 3
K242786 - Rachel Franco Page 3
See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
J Angelo Green -S
J. Angelo Green, Ph.D.
Assistant Director
DHT1A: Division of Ophthalmic Devices
OHT1: Office of Ophthalmic, Anesthesia,
Respiratory, ENT, and Dental Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
Page 4
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Form Approved: OMB No. 0910-0120
Expiration Date: 07/31/2026
See PRA Statement below.
Indications for Use
Submission Number (if known)
K242786
Device Name
TearCare MGX System
Indications for Use (Describe)
The TearCare MGX System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.
Type of Use (Select one or both, as applicable)
☒ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Page 5
TearCare MGX System
K242786 S002 Page 1 of 7
510(k) SUMMARY
Submitter Information
510(k) Owner: Sight Sciences, Inc.
4040 Campbell Ave., Suite 100
Menlo Park, CA 94025
Tel: (877) 266-1144
Contact Person: Rachel M. Franco
Principal Regulatory Affairs Specialist
4040 Campbell Ave., Suite 100
Menlo Park, CA 94025
Tel: 408-221-7376
Date Prepared: April 9, 2025
Device Name and Classification
TRADE NAME: TearCare MGX System
COMMON NAME: N/A
CLASSIFICATION NAME: Eyelid Thermal Pulsation System
REGULATION NUMBER: 21 CFR 886.5200
DEVICE CLASSIFICATION: Class II
PRODUCT CODE: ORZ
Predicate Device
Device Name: TearCare MGX System
510(k) Holder: Sight Sciences, Inc.
510(k) Number: K231084
Clearance Date: December 27, 2023
Indications for Use
The TearCare MGX™ System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.
510(k) Number: K242786
Page 6
TearCare MGX System
510(k) SUMMARY
Submitter Information
510(k) Number: K242786
510(k) Owner: Sight Sciences, Inc.
4040 Campbell Ave., Suite 100
Menlo Park, CA 94025
Tel: (877) 266-1144
Contact Person: Rachel M. Franco
Principal Regulatory Affairs Specialist
4040 Campbell Ave., Suite 100
Menlo Park, CA 94025
Tel: 408-221-7376
Date Prepared: April 9, 2025
Device Name and Classification
| TRADE NAME: | TearCare MGX System |
|---|---|
| COMMON NAME: | N/A |
| CLASSIFICATION NAME: | Eyelid Thermal Pulsation System |
| REGULATION NUMBER: | 21 CFR 886.5200 |
| DEVICE CLASSIFICATION: | Class II |
| PRODUCT CODE: | ORZ |
Predicate Device
Device Name: TearCare MGX System
510(k) Holder: Sight Sciences, Inc.
510(k) Number: K231084
Clearance Date: December 27, 2023
Indications for Use
The TearCare MGX™ System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.
K242786 S002 Page 1 of 7
Page 7
TearCare MGX System
Device Description
The TearCare MGX System is designed to deliver controlled, precise heat to the tarsal plates and underlying meibomian glands of the eyelids for 15 minutes, followed by an optional warming hold time of up to 10 minutes to allow for manual expression. The TearCare MGX System is comprised of a reusable SmartHub, SmartCable, Charging Nest and charging adapter, and single use SmartLids. The subject TearCare MGX System is comprised of the components described in Table 1 below.
Table 1 TearCare MGX System components
| Catalog Number | Description |
|---|---|
| 5-118 | TearCare MGX System Technology Kit, which includes: |
| TearCare MGX SmartHub (Cat no. 5-113) | |
| SmartCable (Cat no. 5-115) | |
| Charging Nest and charging adapter (Cat no. 5-112) | |
| 5-109 | One (1) packaged pair of non-sterile, single-use TearCare MGX SmartLids (each pair includes one left and one right SmartLid) |
The TearCare MGX System is operated by an eye care practitioner, who affixes the SmartLids to the patient's eyelids, connects the SmartLids to the SmartHub with the SmartCable, and initiates the therapy session on the SmartHub. In the same manner as the predicate device, the system increases the temperature from the lowest warmth setting (41°C) to the highest warmth setting (45°C) when the therapy starts. The SmartHub controls the temperature until the 15-minutes of therapy are complete, at which time the system visually and audibly signals the end of therapy. At the end of the 15-minute core therapy, the TearCare MGX System transitions to an optional Warming Hold Time (WHT) that may last up to a maximum of 10 minutes. WHT holds the temperature at the lowest warmth setting (Warmth setting 1 and temperature set point of 41°C) allowing the eye care practitioner to individually express each eyelid while the lids are warm. To complete the TearCare MGX procedure, the eye care practitioner removes the SmartLid devices one at a time from the patient, then uses the separately available meibomian gland expression forceps (Clearance Assistant) to manually express the meibomian glands immediately following the eyelid heat therapy. Heat is discontinued once the SmartLid is removed prior to expression, at the end of the optional 10-minute WHT, or at any time the eye care practitioner utilizes the SmartHub control to interrupt (pause or stop) treatment.
The subject TearCare MGX System is technologically the same as the predicate TearCare MGX System cleared under 510(k) K231084. Notably, there are no changes to the system impacting thermal exposure and limits regarding temperature control and regulation. The subject device of this submission proposes changes to the TearCare MGX System that impact the Instructions for Use (IFU), rather than a device technological change. The procedural instructions for use are updated with additional instruction for the application of the SmartLids including an earpiece fitment check to assess whether the ear loop requires further support. A comparison of the technological characteristics between the subject TearCare MGX System compared with the predicate TearCare System device is shown in Table 2 below.
K242786 S002 Page 2 of 7
Page 8
TearCare MGX System
K242786 S002 Page 3 of 7
Table 2 Comparison of Technological Characteristics with the Predicate Device
| Characteristic | TearCare MGX System
(Sight Sciences, Inc.)
Subject Device | TearCare MGX System
(Sight Sciences, Inc.)
K231084
Predicate Device | Comparison between TearCare System Subject and Predicate Device |
|---|---|---|---|
| Device Classification | Class II | Class II | Equivalent |
| Classification Product Code | ORZ | ORZ | Equivalent |
| Regulation Number | 886.5200 | 886.5200 | Equivalent |
| Indications For Use | The TearCare MGX System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. | The TearCare MGX System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. | Equivalent |
| Technological Characteristics |
| Device Description | • Disposable SmartLid components are attached to the external surface of the eyelids and connect to a reusable SmartHub controller which generates the heat that is delivered to the eyelids
• A separate, sterile disposable Clearance Assistant™ is used in conjunction with the TearCare MGX System to perform manual expression of the meibomian glands immediately following heat treatment with TearCare | • Disposable SmartLid components are attached to the external surface of the eyelids and connect to a reusable SmartHub controller which generates the heat that is delivered to the eyelids
• A separate, sterile disposable Clearance Assistant™ is used in conjunction with the TearCare MGX System to perform manual expression of the meibomian glands immediately following heat treatment with TearCare | Equivalent |
| Sterilization | The TearCare MGX SmartHub, SmartCable, Charging Nest and SmartLids are non-sterile | The TearCare MGX SmartHub, SmartCable, Charging Nest and SmartLids are non-sterile | Equivalent |
| Single Use or Reusable | • SmartLids: single use | • SmartLids: single use | Equivalent |
K242786 S002 Page 3 of 7
Page 9
TearCare MGX System
Table 2 Comparison of Technological Characteristics with the Predicate Device
| Characteristic | TearCare MGX System
(Sight Sciences, Inc.)
Subject Device | TearCare MGX System
(Sight Sciences, Inc.)
K231084
Predicate Device | Comparison between TearCare System Subject and Predicate Device |
|---|---|---|---|
| Device Classification | Class II | Class II | Equivalent |
| Classification Product Code | ORZ | ORZ | Equivalent |
| Regulation Number | 886.5200 | 886.5200 | Equivalent |
| Indications For Use | The TearCare MGX System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. | The TearCare MGX System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. | Equivalent |
| Technological Characteristics |
| Device Description | • Disposable SmartLid components are attached to the external surface of the eyelids and connect to a reusable SmartHub controller which generates the heat that is delivered to the eyelids
• A separate, sterile disposable Clearance Assistant™ is used in conjunction with the TearCare MGX System to perform manual expression of the meibomian glands immediately following heat treatment with TearCare | • Disposable SmartLid components are attached to the external surface of the eyelids and connect to a reusable SmartHub controller which generates the heat that is delivered to the eyelids
• A separate, sterile disposable Clearance Assistant™ is used in conjunction with the TearCare MGX System to perform manual expression of the meibomian glands immediately following heat treatment with TearCare | Equivalent |
| Sterilization | The TearCare MGX SmartHub, SmartCable, Charging Nest and SmartLids are non-sterile | The TearCare MGX SmartHub, SmartCable, Charging Nest and SmartLids are non-sterile | Equivalent |
| Single Use or Reusable | • SmartLids: single use | • SmartLids: single use | Equivalent |
K242786 S002 Page 3 of 7
Page 10
TearCare MGX System
K242786 S002 Page 4 of 7
| Characteristic | TearCare MGX System
(Sight Sciences, Inc.)
Subject Device | TearCare MGX System
(Sight Sciences, Inc.)
K231084
Predicate Device | Comparison between TearCare System Subject and Predicate Device |
|---|---|---|---|
| | • SmartHub, SmartCable, and Charging Nest: reusable | • SmartHub, SmartCable, and Charging Nest: reusable | |
| Operation Control | Eye Care Practitioner | Eye Care Practitioner | Equivalent |
| Mechanism for Heat Generation | Polymer encapsulated resistive heating element | Polymer encapsulated resistive heating element | Equivalent |
| Power source | Batteries, DC power | Batteries, DC power | Equivalent |
| Point of Use | In-Office | In-Office | Equivalent |
| Duration of Treatment | 15 minutes of heat treatment with the TearCare MGX System, followed manual expression of all four eyelids using the Clearance Assistant which typically requires 5-10 minutes.
An optional warming hold time is available following heat treatment to allow flexibility to perform expression while the eyelids are warm. | 15 minutes of heat treatment with the TearCare MGX System, followed manual expression of all four eyelids using the Clearance Assistant which typically requires 5-10 minutes.
An optional warming hold time is available following heat treatment to allow flexibility to perform expression while the eyelids are warm. | Equivalent |
| Temperature regulation | Temperature at the SmartLids are continuously monitored by the SmartHub to ensure it does not exceed the maximum allowable temperature | Temperature at the SmartLids are continuously monitored by the SmartHub to ensure it does not exceed the maximum allowable temperature | Equivalent |
| Therapeutic Temperature Range | Automatic ramp from 41 to 45°C in five 1°C steps. User can adjust to any of these 5 temperature settings | Automatic ramp from 41 to 45°C in five 1°C steps. User can adjust to any of these 5 temperature settings | Equivalent |
| Temperature Accuracy | ± 0.7°C | ± 0.7°C | Equivalent |
| Maximum Sustainable Therapeutic Temperature (i.e., for the duration of the procedure) | 46.74°C | 46.74°C | Equivalent |
K242786 S002 Page 4 of 7
Page 11
TearCare MGX System
| Characteristic | TearCare MGX System
(Sight Sciences, Inc.)
Subject Device | TearCare MGX System
(Sight Sciences, Inc.)
K231084
Predicate Device | Comparison between TearCare System Subject and Predicate Device |
|---|---|---|---|
| Maximum Absolute Temperature Limit (at any exposure time) | 47°C | 47°C | Equivalent |
| Maximum Outer Eyelid Surface Temperature Limit (Safety Limit) | 46.99°C for 2 seconds prior to automatic temperature downregulation | 46.99°C for 2 seconds prior to automatic temperature downregulation | Equivalent |
| Rate of Heating (time to reach target temperature) |